Gilead Sciences: Pay

Gilead Sciences paid its 5 named executives $65.4M in total in FY2025 (Dec). CEO Daniel P. O’Day was paid $28.4M of that.

Pay$100 in the stock at the end of FY18 → $231
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Daniel P. O’DayChairman and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
FY2020 (Dec)
FY2019 (Dec)
7 years
Dietmar BergerM.D., Ph.D. Chief Medical Officer
FY2025 (Dec)
1 year
Johanna MercierChief Commercial and Corporate Affairs Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
FY2020 (Dec)
FY2019 (Dec)
7 years
Andrew D. DickinsonChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
FY2020 (Dec)
FY2019 (Dec)
7 years
Deborah H. TelmanFormer Executive Vice President, Corporate Affairs and General Counsel
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 8 peers with pay on file was $26.1M. The CEO of Gilead Sciences was paid $28.4M, 9% above the median.

  1. 1Eli Lilly & Co
  2. 2Johnson & Johnson
  3. 3AbbVie
  4. 4Gilead Sciences
  5. 5Pfizer
  6. 6Amgen
  7. 7Bristol Myers Squibb
  8. 8Merck & Co.
  9. 9Regeneron Pharmaceuticals
  10. 10BiogenNot disclosed
  11. 11Vertex Pharmaceuticals IncorporatedNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.